# Immune Checkpoint Inhibitor and MR-guided SBRT for Limited Progressive Metastatic Carcinoma.

> **NCT04376502** · NA · TERMINATED · sponsor: **Baptist Health South Florida** · enrollment: 12 (actual)

## Conditions studied

- Metastatic Carcinoma

## Interventions

- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT04376502
- **Lead sponsor:** Baptist Health South Florida
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-08
- **Primary completion:** 2023-06-16
- **Final completion:** 2023-10-04
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Poor enrollment
- **Last updated:** 2025-01-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04376502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04376502, "Immune Checkpoint Inhibitor and MR-guided SBRT for Limited Progressive Metastatic Carcinoma.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04376502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*